GO:0045719 negative regulation of glycogen biosynthetic process: Regulatory Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045719 describes any process that stops, prevents, or reduces the frequency, rate or extent of glycogen biosynthesis, the pathway that builds the glucose storage polymer glycogen.
• Glycogen synthase (GYS1/GYS2) is the rate-limiting enzyme of glycogen synthesis, and its inhibition by phosphorylation is a central mechanism of negative regulation.
• Glycogen synthase kinase-3 (GSK3A/GSK3B) phosphorylates and inactivates glycogen synthase, directly linking this GO term to insulin signaling, Wnt signaling, and cellular stress responses.
• Hormonal and metabolic signals, including insulin, glucagon, epinephrine, and supraphysiological sex steroids, modulate glycogen biosynthetic flux through kinase and phosphatase cascades.
• Dysregulation of glycogen biosynthetic control is implicated in type 2 diabetic kidney disease, metabolic disorders, and cancer cell metabolism.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of negative regulators of glycogen synthesis in relevant cell types.
Description
Glycogen is a branched glucose polymer that serves as a rapidly mobilizable energy reserve in liver, muscle, and other tissues. The biosynthetic process that forms glycogen is tightly controlled, and the Gene Ontology term GO:0045719, negative regulation of glycogen biosynthetic process, captures all molecular events that stop, prevent, or reduce the rate of glycogen formation. This term is essential for annotating signaling pathways that tune glycogen storage in response to nutritional, hormonal, and stress cues. The rate-limiting step of glycogen synthesis is catalyzed by glycogen synthase, whose activity is suppressed by phosphorylation. Among the best-characterized negative regulators is glycogen synthase kinase-3 (GSK3), which phosphorylates glycogen synthase and thereby reduces its catalytic activity. Because GSK3 is itself inhibited by insulin signaling, this kinase provides a direct molecular link between extracellular signals and the negative control of glycogen biosynthesis. Beyond GSK3, other kinases and hormonal inputs, including supraphysiological doses of 17beta-estradiol or testosterone, can negatively regulate glucose metabolism and glycogen synthesis in human myotubes. In disease contexts, redox-sensitive GSK3beta has been identified as a key regulator of glomerular podocyte injury in type 2 diabetic kidney disease, illustrating how negative regulation of glycogen biosynthesis intersects with metabolic pathology. Plant homologs of GSK3, such as the maize kinase ZmSK1, also participate in stress signaling, underscoring the evolutionary conservation of these regulatory modules. For researchers, GO:0045719 provides a structured framework to annotate genes, interpret omics data, and design experiments that test how specific perturbations alter glycogen storage.
negative regulation of glycogen biosynthetic process At A Glance
| GO ID | GO:0045719 |
|---|---|
| GO term | negative regulation of glycogen biosynthetic process |
| Ontology | biological_process |
| Definition | Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of glycogen. |
| Synonym | down regulation of glycogen biosynthetic process; down-regulation of glycogen biosynthetic process; downregulation of glycogen biosynthetic process; inhibition of glycogen biosynthetic process; negative regulation of glycogen anabolism; negative regulation of glycogen biosynthesis; negative regulation of glycogen formation; negative regulation of glycogen synthesis |
| Major function | Suppression of glycogen synthesis through inhibition of glycogen synthase and upstream signaling pathways. |
| Key enzymes | Glycogen synthase (GYS1, GYS2); glycogen synthase kinase-3 (GSK3A, GSK3B). |
| Regulatory inputs | Insulin, glucagon, epinephrine, sex steroids, cellular redox state. |
| Disease relevance | Type 2 diabetic kidney disease, metabolic disorders, cancer metabolism. |
What Is GO:0045719?
GO:0045719, negative regulation of glycogen biosynthetic process, is defined as any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of glycogen. In practical terms, it encompasses signaling events, post-translational modifications, and transcriptional or allosteric mechanisms that suppress the synthesis of glycogen from glucose precursors. This term is a biological_process annotation and is distinct from positive regulation of glycogen biosynthesis and from regulation of glycogen catabolism.
Why Is negative regulation of glycogen biosynthetic process Important in Cell Biology?
Understanding negative regulation of glycogen biosynthetic process is critical because glycogen storage must be precisely matched to energy demand and nutrient availability. Excessive or inappropriate glycogen synthesis contributes to metabolic dysfunction, while failure to suppress glycogen synthesis when glucose is scarce can waste energy and disrupt cellular homeostasis. The GSK3-glycogen synthase axis is a paradigmatic example of how phosphorylation cascades integrate hormonal signals to control a biosynthetic pathway. In disease, redox-sensitive GSK3beta drives podocyte injury in type 2 diabetic kidney disease, directly connecting negative regulation of glycogen biosynthesis to organ damage. Hormonal perturbations, such as supraphysiological sex steroid exposure, can also negatively regulate glucose metabolism in human myotubes, highlighting endocrine control of this process. Comparative studies in plants, such as the maize GSK3-like kinase ZmSK1, reveal conserved principles of kinase-mediated negative regulation in stress responses. Thus, GO:0045719 is a nexus for metabolic signaling, disease mechanism, and therapeutic target discovery.
• Provides a controlled vocabulary for annotating genes that suppress glycogen synthesis in metabolic pathways.
• Links insulin signaling to glycogen storage through GSK3-mediated inhibition of glycogen synthase.
• Explains how hormonal signals such as glucagon and epinephrine reduce glycogen synthesis.
• Connects redox-sensitive GSK3beta to podocyte injury in type 2 diabetic kidney disease.
• Highlights endocrine disruption of glucose metabolism by supraphysiological sex steroids in human myotubes.
• Supports comparative studies of GSK3-like kinases in plants, such as ZmSK1 in drought tolerance.
• Guides CRISPR-based dissection of causal regulators in metabolic disease models.
• Informs drug discovery targeting GSK3 and related kinases for metabolic disorders.
• Enables interpretation of omics data by grouping genes under a shared regulatory process.
• Facilitates cross-species translation of glycogen metabolism research.
What Happens During negative regulation of glycogen biosynthetic process?
Initiation by hormonal and metabolic signals
In simple terms: The body sends chemical signals that tell cells to stop making glycogen when energy is plentiful or when storage is not needed.
Negative regulation of glycogen biosynthesis begins with extracellular or intracellular signals that indicate a reduced need for glycogen storage. Insulin, glucagon, epinephrine, and sex steroids can modulate the activity of kinases and phosphatases that control glycogen synthase. In isolated hepatocytes, regulation of glycogen synthase activation has been directly demonstrated, showing that hormonal cues rapidly alter the enzyme's phosphorylation state. Supraphysiological doses of 17beta-estradiol or testosterone negatively regulate glucose metabolism in human myotubes, providing evidence that endocrine signals can suppress glycogen biosynthetic flux.
Phosphorylation of glycogen synthase
In simple terms: Enzymes add phosphate groups to glycogen synthase, which acts like a switch that turns the enzyme off.
The central molecular event in negative regulation of glycogen biosynthesis is the phosphorylation of glycogen synthase, which reduces its catalytic activity. Glycogen synthase kinase-3 (GSK3) is a well-characterized kinase that phosphorylates glycogen synthase and inhibits its function. GSK3 exists as two isoforms, GSK3A and GSK3B, and both can contribute to glycogen synthase inhibition. This phosphorylation-dependent inactivation is reversible, allowing rapid reactivation when glycogen synthesis is again required.
GSK3 regulation by upstream pathways
In simple terms: The enzymes that shut down glycogen synthesis are themselves controlled by other signals, creating a layered switch.
GSK3 activity is regulated by multiple upstream inputs, including insulin signaling, Wnt signaling, and cellular redox state. Insulin promotes GSK3 inhibition, which in turn relieves the negative regulation of glycogen synthase and favors glycogen synthesis. Redox-sensitive GSK3beta is a key regulator of glomerular podocyte injury in type 2 diabetic kidney disease, indicating that oxidative stress can modulate GSK3 function in disease. Alternative splicing of GSK3 transcripts adds another layer of regulatory complexity.
Dephosphorylation and reversibility
In simple terms: The off switch can be reset by removing phosphate groups, allowing glycogen synthesis to restart.
Protein phosphatases can dephosphorylate glycogen synthase and reverse the inhibitory phosphorylation, thereby restoring its activity. The balance between kinase and phosphatase activities determines the net rate of glycogen biosynthesis at any given moment. This reversibility is essential for dynamic metabolic control and is a target of hormonal regulation.
Integration with cellular stress and disease pathways
In simple terms: Stress and disease can hijack the off switch, leading to metabolic problems.
Negative regulation of glycogen biosynthesis intersects with stress-responsive pathways. In plants, the maize GSK3-like kinase ZmSK1 negatively regulates drought tolerance by phosphorylating the transcription factor ZmCPP2, demonstrating that GSK3-like kinases couple stress signaling to downstream transcriptional programs. In human disease, GSK3beta-mediated regulation contributes to podocyte injury in type 2 diabetic kidney disease, linking this GO term to organ pathology. These examples show that the same regulatory logic operates across kingdoms and disease contexts.
Key Genes Involved in GO:0045719 negative regulation of glycogen biosynthetic process
The following genes and proteins are experimentally implicated in the negative regulation of glycogen biosynthetic process or in closely related regulatory pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GYS1 | Muscle glycogen synthase; rate-limiting enzyme of glycogen synthesis | Phosphorylation by GSK3 inhibits its activity, a key node in negative regulation. |
| GYS2 | Liver glycogen synthase; rate-limiting enzyme of hepatic glycogen synthesis | Hormonal control of hepatic glycogen synthase activation has been demonstrated. |
| GSK3A | Glycogen synthase kinase-3 alpha; phosphorylates and inhibits glycogen synthase | Isoform-specific roles in glycogen metabolism and signaling. |
| GSK3B | Glycogen synthase kinase-3 beta; phosphorylates and inhibits glycogen synthase | Redox-sensitive regulator of podocyte injury in type 2 diabetic kidney disease. |
| ZmSK1 | Maize GSK3-like kinase; phosphorylates transcription factor ZmCPP2 | Negatively regulates drought tolerance, illustrating conserved GSK3-like function. |
| ZmCPP2 | Transcription factor phosphorylated by ZmSK1 | Downstream effector of GSK3-like kinase signaling in plants. |
| INSR | Insulin receptor; initiates insulin signaling | Upstream of GSK3 inhibition and glycogen synthase activation. |
| IRS1 | Insulin receptor substrate 1; adaptor in insulin signaling | Links insulin signaling to downstream kinases controlling glycogen synthesis. |
| AKT1 | Protein kinase B; phosphorylates and inhibits GSK3 | Connects insulin signaling to relief of glycogen synthase inhibition. |
| PPP1CA | Protein phosphatase 1 catalytic subunit alpha; dephosphorylates glycogen synthase | Reverses inhibitory phosphorylation and promotes glycogen synthesis. |
| PPP1R3A | Protein phosphatase 1 regulatory subunit 3A; targets PP1 to glycogen | Regulates glycogen synthase dephosphorylation in muscle. |
| PPP1R3B | Protein phosphatase 1 regulatory subunit 3B; targets PP1 to glycogen in liver | Controls hepatic glycogen synthase activity. |
| ESR1 | Estrogen receptor alpha; mediates estrogen signaling | Supraphysiological estradiol negatively regulates glucose metabolism in myotubes. |
| AR | Androgen receptor; mediates testosterone signaling | Supraphysiological testosterone negatively regulates glucose metabolism in myotubes. |
| PRKAA1 | AMP-activated protein kinase catalytic subunit alpha-1; energy sensor | Can phosphorylate and regulate glycogen synthase and related metabolic enzymes. |
| PRKAA2 | AMP-activated protein kinase catalytic subunit alpha-2; energy sensor | Contributes to metabolic regulation of glycogen synthesis. |
| SLC2A4 | GLUT4 glucose transporter; mediates glucose uptake | Glucose availability influences glycogen biosynthetic flux. |
| HK2 | Hexokinase 2; phosphorylates glucose to glucose-6-phosphate | Upstream of glycogen synthesis; its activity affects substrate supply. |
How Is negative regulation of glycogen biosynthetic process Regulated?
Negative regulation of glycogen biosynthetic process is controlled by a multilayered signaling network. Insulin signaling activates AKT, which phosphorylates and inhibits GSK3, thereby relieving the inhibitory phosphorylation of glycogen synthase and promoting glycogen synthesis. Conversely, glucagon and epinephrine elevate cAMP and activate kinases that ultimately inhibit glycogen synthase. Cellular redox state modulates GSK3beta activity, as shown in glomerular podocytes under diabetic conditions. Supraphysiological sex steroids can negatively regulate glucose metabolism in human myotubes, indicating endocrine modulation of this pathway. In plants, GSK3-like kinases such as ZmSK1 are regulated by drought stress and phosphorylate transcription factors to control downstream responses. These regulatory inputs converge on glycogen synthase and its upstream kinases and phosphatases, determining the net rate of glycogen biosynthesis.
negative regulation of glycogen biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GSK3B | Type 2 diabetic kidney disease; podocyte injury | Podocyte-specific knockout or point-mutation models |
| GYS1 | Glycogen storage and metabolic disorders | GYS1 knockout or knock-in cell lines |
| GYS2 | Hepatic glycogen metabolism disorders | Hepatocyte knockout or overexpression models |
| ESR1 | Endocrine regulation of glucose metabolism | Myotube overexpression or knockout models |
| AR | Androgen effects on glucose metabolism | Myotube overexpression or knockout models |
Type 2 diabetic kidney disease
Redox-sensitive GSK3beta is a key regulator of glomerular podocyte injury in type 2 diabetic kidney disease. Because GSK3beta phosphorylates and inhibits glycogen synthase, its dysregulation may contribute to altered glycogen metabolism in podocytes. This connection places GO:0045719 at the intersection of metabolic signaling and renal pathology.
Metabolic disorders and insulin resistance
Insulin signaling normally inhibits GSK3 and promotes glycogen synthesis. When insulin signaling is impaired, GSK3 remains active and continues to suppress glycogen synthase, potentially exacerbating hyperglycemia and metabolic dysfunction. Supraphysiological sex steroids can also negatively regulate glucose metabolism in human myotubes, suggesting endocrine contributions to metabolic disease.
Cancer cell metabolism
GSK3 isoforms are involved in diverse cellular processes, including alternative splicing regulation, which can affect cancer cell behavior. While direct evidence linking GO:0045719 to cancer is limited in the provided literature, the broad role of GSK3 in signaling and metabolism makes it a plausible contributor to cancer metabolic reprogramming.
Plant stress responses
The maize GSK3-like kinase ZmSK1 negatively regulates drought tolerance by phosphorylating the transcription factor ZmCPP2. This demonstrates that negative regulation of biosynthetic processes by GSK3-like kinases is conserved beyond mammals and can influence organismal stress responses.
From negative regulation of glycogen biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GSK3B increase glycogen synthase activity? | GSK3B knockout cell line |
| Does a specific phosphorylation site on GYS1 control its activity? | GYS1 point-mutation knock-in |
| Can a tagged GYS1 reveal its interaction partners? | Tagged knock-in of GYS1 |
| Does overexpression of GSK3A suppress glycogen synthesis? | GSK3A overexpression cell model |
| How do sex steroids affect glycogen biosynthetic genes? | ESR1 or AR overexpression in myotubes |
| Is ZmSK1 required for drought-induced transcriptional changes? | ZmSK1 knockout in maize |
How to Study the negative regulation of glycogen biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Western blot | Protein expression and phosphorylation status | Assessing glycogen synthase and GSK3 phosphorylation |
| Glycogen assay | Cellular glycogen content | Functional readout of glycogen synthesis |
| Kinase assay | Enzymatic activity of GSK3 or other kinases | Direct measurement of negative regulator activity |
| RNA-seq | Transcriptome-wide gene expression | Identifying genes co-regulated with glycogen metabolism |
| Proteomics | Protein abundance and modifications | Discovering novel regulators and interaction partners |
| CRISPR knockout | Loss-of-function phenotypes | Testing causal roles of candidate genes |
| CRISPR knock-in | Precise allele modification | Introducing tags or point mutations |
| Overexpression | Gain-of-function phenotypes | Testing sufficiency of a regulator |
Phosphorylation analysis
Western blotting with phospho-specific antibodies against glycogen synthase and GSK3 can quantify the phosphorylation state that governs negative regulation. This method is widely used to assess changes in kinase activity in response to hormonal or metabolic stimuli.
Glycogen content assays
Colorimetric or fluorometric assays measure glycogen levels in cells or tissues, providing a functional readout of changes in glycogen biosynthetic flux. These assays are essential for validating whether a genetic perturbation alters the net rate of glycogen synthesis.
Kinase activity assays
In vitro kinase assays using recombinant GSK3 and glycogen synthase as substrates can directly measure the catalytic activity of negative regulators. Such assays help distinguish between changes in kinase expression and changes in specific activity.
Transcriptomic and proteomic profiling
RNA-seq and proteomics can identify global changes in genes and proteins associated with glycogen metabolism following perturbations. These approaches are useful for discovering novel regulators and for validating pathway-level effects.
How CRISPR Can Be Used to Study GO:0045719 negative regulation of glycogen biosynthetic process
Knockout
CRISPR knockout of GSK3B or GYS1 can test whether these genes are required for negative regulation of glycogen biosynthesis. For example, GSK3B knockout in podocytes could reveal its role in diabetic kidney disease. Knockout of ZmSK1 in maize can test its function in drought tolerance.
Point Mutation
Point mutations can be introduced into phosphorylation sites of glycogen synthase to determine which residues mediate inhibition by GSK3. This approach provides precise mechanistic insight beyond simple knockout.
Knock-in
Knock-in of epitope tags or fluorescent reporters into endogenous GYS1 or GSK3B loci enables real-time tracking of protein localization and interactions. Tagged knock-in models are valuable for studying dynamic regulation.
Overexpression
Overexpression of GSK3A or GSK3B can test whether increased kinase levels are sufficient to suppress glycogen synthesis. Similarly, overexpression of ESR1 or AR can model the effects of sex steroids on glucose metabolism.
How EDITGENE Supports negative regulation of glycogen biosynthetic process Research
Researchers studying negative regulation of glycogen biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in suppressing glycogen synthesis or whether it is merely correlated with pathway activity. CRISPR-based models provide the gold standard for establishing causality, and EDITGENE offers a comprehensive suite of services to generate and characterize such models.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of glycogen biosynthetic process research.
Frequently Asked Questions About negative regulation of glycogen biosynthetic process
What is GO:0045719?
GO:0045719 is the Gene Ontology term for negative regulation of glycogen biosynthetic process, defined as any process that stops, prevents, or reduces the frequency, rate or extent of glycogen formation.
What genes are involved in negative regulation of glycogen biosynthetic process?
Key genes include GYS1, GYS2, GSK3A, GSK3B, and upstream signaling components such as INSR and AKT1.
How does GSK3 inhibit glycogen synthesis?
GSK3 phosphorylates glycogen synthase, reducing its catalytic activity and thereby suppressing glycogen biosynthesis.
What hormones regulate glycogen biosynthesis?
Insulin promotes glycogen synthesis by inhibiting GSK3, while glucagon and epinephrine oppose it; sex steroids can also negatively regulate glucose metabolism.
Is negative regulation of glycogen biosynthesis relevant to disease?
Yes, redox-sensitive GSK3beta is implicated in podocyte injury in type 2 diabetic kidney disease, linking this process to metabolic pathology.
What experimental models are used to study this process?
CRISPR knockout, point-mutation, knock-in, and overexpression cell models, as well as glycogen assays and kinase assays, are commonly used.
Can CRISPR be used to study glycogen synthesis regulation?
Yes, CRISPR knockout of GSK3B or GYS1 can test causal roles in glycogen biosynthesis.
What is the role of GSK3 in plants?
The maize GSK3-like kinase ZmSK1 negatively regulates drought tolerance by phosphorylating the transcription factor ZmCPP2.
How is glycogen synthase activity measured?
Glycogen synthase activity can be assessed by kinase assays, phosphorylation-specific western blots, and glycogen content assays.
What services does EDITGENE offer for glycogen metabolism research?
EDITGENE provides knockout, point-mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics services.
Conclusion
GO:0045719, negative regulation of glycogen biosynthetic process, is a fundamental biological process that controls glycogen storage through phosphorylation-dependent inhibition of glycogen synthase and upstream signaling cascades. Its dysregulation is linked to metabolic diseases such as type 2 diabetic kidney disease, and its components are conserved across species. CRISPR-based models offer powerful tools to dissect the causal roles of specific genes in this pathway, and EDITGENE provides end-to-end services to support such research.
References
- 1. Xiang Y et al.. 2025. The maize GSK3-like kinase ZmSK1 negatively regulates drought tolerance by phosphorylating the transcription factor ZmCPP2.. Plant Cell 37(2) PMID: 39928574
- 4. Pugazhenthi S et al.. 1995. Regulation of glycogen synthase activation in isolated hepatocytes.. Mol Cell Biochem 149-150:95-101 PMID: 8569754
- 5. Liu X et al.. 2018. Glycogen synthase kinase-3 and alternative splicing.. Wiley Interdiscip Rev RNA 9(6):e1501 PMID: 30118183
- 6. Chen M et al.. 2024. The redox-sensitive GSK3β is a key regulator of glomerular podocyte injury in type 2 diabetic kidney disease.. Redox Biol 72:103127 PMID: 38527400
- 8. Garrido P et al.. 2014. Negative regulation of glucose metabolism in human myotubes by supraphysiological doses of 17β-estradiol or testosterone.. Metabolism 63(9):1178-87 PMID: 25034385
